PT-141

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist. It is structurally related to the melanocortin family of peptides and is listed in this catalog as an injectable research compound. PT-141 is supplied for research and professional reference use only and is not approved by the FDA for therapeutic use; nothing in this listing should be read as a treatment, diagnostic, or curative claim. Within the published literature, PT-141 is most often examined for its central, receptor-mediated activity rather than peripheral vascular pathways, a characteristic noted in research as distinguishing it from certain other compounds studied in adjacent areas of investigation. This entry is provided as professional reference information for licensed practitioners evaluating compounds for laboratory and research contexts.

• Investigated in preclinical and exploratory literature for melanocortin receptor (notably MC4R) signaling pathways; individual results vary.
• Studied in research settings for centrally mediated mechanisms reported as distinct from peripheral vascular activity; individual results vary.
• Examined in the literature as a model compound for characterizing melanocortin-mediated neural signaling; individual results vary.
• Referenced in research contexts characterizing melanocortin receptor activity within central nervous system pathways; individual results vary.
• Of academic interest in studies describing receptor-binding and downstream signaling profiles of melanocortin agonists; individual results vary.

For research and professional use only. Supplied as a lyophilized powder; reconstitute with bacteriostatic water (or another sterile diluent selected by the ordering provider), adding the diluent slowly against the vial wall and allowing the powder to dissolve without vigorous agitation. Store the sealed, unreconstituted vial protected from light; refrigeration is commonly referenced for longer-term storage, while lyophilized material may be held at cooler temperatures per the provider's laboratory standards. After reconstitution, keep refrigerated, protect from light, avoid repeated freeze-thaw cycles, and handle the material using appropriate sterile technique. Avoid prolonged exposure to heat or direct light. This is reference information only and not medical advice; all clinical and research protocols, including any handling, preparation, and use decisions, are determined solely by the licensed ordering provider.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

PT-141 is described in the literature as a non-selective agonist of melanocortin receptors, with particular research attention given to the melanocortin-4 receptor (MC4R) and, to a lesser degree, the melanocortin-3 receptor (MC3R) within the central nervous system. The proposed mechanism centers on activation of these receptors in hypothalamic and related neural pathways, which researchers have studied as a route reported to be distinct from peripheral vascular or hormonal mechanisms. Because activity is described as centrally mediated, investigators have examined its receptor-binding profile and downstream signaling as a model for melanocortin-driven processes. These mechanistic descriptions reflect findings reported in preclinical and exploratory literature; individual results vary and no therapeutic outcome is claimed or implied.